MULTI-001 Nivolumab v7 MULTI-002 Carboplatin and etoposide v1 MULTI-014 Irinotecan & Capecitabine v1 MULTI-018 Larotrectinib v2 MULTI-019 Entrectinib v1
UGI-023 Sorafenib v7 UGI-037 DCF v3 UGI-039 Modified Folfirinox (palliative) v5 UGI-040 Everolimus NET v4 UGI-045 Capecitabine (intermittent dose) & Oxaliplatin v3 UGI-047 Nab-Paclitaxel (Abraxane) ® Gemcitabine v6 UGI-048 Regorafenib v3 UGI-058 FLOT v2 UGI-059 Capecitabine for resected biliary tract cancer v1 UGI-060 Lenvatinib (LENVIMA®) v2 UGI-061 Folfirinox (adjuvant) v1 UGI-062 OX (reduced dose) v1 UGI-065 Nivolumab for metastatic oesophageal cancer (EAMs) v1 UGI-066 Atezolizumab and Bevacizumab v2 UGI-067 Pemigatinib v2 UGI-069 Pembrolizumab in combination with chemotherapy v1 UGI-070 OX (standard dose, continuous capecitabine) v1
